|
Monday 30th August 2021 |
Text too small? |
Rua Bioscience announces its annual financial results for the 12 months ended 30 June 2021 (FY21). In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model.
Rua’s commitment to creating shareholder value has seen it working on two fronts - preparing to enter local and global medicinal cannabis markets by calendar year end 2021 / early 2022 and developing long-term opportunities across the medicinal cannabis value chain.
Outlook
Rua Bioscience is a pharmaceutical company aiming to lead the production of cannabinoid-derived medicines. The Company has a focused and realistic export strategy, with a clear path to revenue and a view extending along the medicinal cannabis value chain. Proceeds from the IPO continue to fund Rua Bioscience's next growth stage, building long-term resilience and accelerating growth.
Please see the links below for details
Rua Bioscience FY21 Annual Results Market Announcement
Financial Results Announcement FY21
Rua Bioscience Limited FY21 Financial Statements
Source: Rua Bioscience Limited
No comments yet
AFI - Dividend Guidance for FY27 and Move to Quarterly Dividends
SKO - Serko FY27 Interim Results Announcement Date - 16 November
NZK - Proposed Share Transaction Requiring Shareholder Approval
BIF - capital commitment made to BIF
HGH - Heartland shareholders approve proposed TSB merger
TWL Annual General Shareholders' Meeting 2026 Results
TEM - Transaction in Own Shares
BIT Transaction in Own Shares
WHS - The Warehouse Group FY26 Annual Results
WHS - The Warehouse Group to hold Investor Day